Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ENLV Stock Forecast 2025-2026
$0.98
Current Price
$23.25M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ENLV Price Targets
+1,233.3%
To High Target of $13.00
+925.6%
To Median Target of $10.00
+617.9%
To Low Target of $7.00
ENLV Price Momentum
-2.0%
1 Week Change
+2.1%
1 Month Change
-30.0%
1 Year Change
-16.2%
Year-to-Date Change
-44.6%
From 52W High of $1.76
+20.4%
From 52W Low of $0.81
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Enlivex (ENLV) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ENLV and similar high-potential opportunities.
Latest ENLV Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, ENLV has a bullish consensus with a median price target of $10.00 (ranging from $7.00 to $13.00). Currently trading at $0.98, the median forecast implies a 925.6% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jason Kolbert at D. Boral Capital, projecting a 1,233.3% upside. Conversely, the most conservative target is provided by Raghuram Selvaraju at HC Wainwright & Co., suggesting a 617.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ENLV Analyst Ratings
2
Buy
0
Hold
0
Sell
ENLV Price Target Range
Low
$7.00
Average
$10.00
High
$13.00
Current: $0.98
Latest ENLV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ENLV.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 21, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $13.00 |
| Apr 3, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $13.00 |
| Mar 24, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $7.00 |
| Mar 3, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $13.00 |
| Feb 7, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $13.00 |
| Dec 11, 2024 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $13.00 |
| Dec 3, 2024 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $13.00 |
| Nov 14, 2024 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $13.00 |
| Sep 27, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $6.00 |
| Sep 26, 2024 | EF Hutton | Jason Kolbert | Buy | Maintains | $13.00 |
| Sep 24, 2024 | EF Hutton | Jason Kolbert | Buy | Maintains | $13.00 |
| Sep 9, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $6.00 |
| Aug 27, 2024 | EF Hutton | Jason Kolbert | Buy | Initiates | $13.00 |
| Jun 11, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $6.00 |
| Apr 23, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $7.00 |
| Apr 12, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $7.00 |
| Sep 25, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $12.00 |
| Aug 1, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $15.00 |
| Apr 24, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $15.00 |
| Apr 5, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $15.00 |
Enlivex Therapeutics Ltd. (ENLV) Competitors
The following stocks are similar to Enlivex based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Enlivex Therapeutics Ltd. (ENLV) Financial Data
Enlivex Therapeutics Ltd. has a market capitalization of $23.25M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -55.9%.
Valuation Metrics
Market Cap
$23.25M
Enterprise Value
$97,714
P/E Ratio
0.0x
PEG Ratio
-1.7x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+101.8%
Current Ratio
6.8x
Debt/Equity
2.3x
ROE
-55.9%
ROA
-30.1%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Enlivex Therapeutics Ltd. (ENLV) Business Model
About Enlivex Therapeutics Ltd.
What They Do
Develops treatments for immune system disorders.
Business Model
The company utilizes its proprietary Allocetra technology to create biopharmaceutical treatments that reprogram the immune system to address severe inflammatory conditions. It aims to generate revenue through the development and commercialization of these innovative therapies, targeting critical health issues like sepsis and other inflammatory diseases.
Additional Information
Headquartered in Ness Ziona, Israel, Enlivex Therapeutics is positioned within the biopharmaceutical industry, focusing on unmet medical needs and improving patient outcomes. Its research has the potential to transform treatment approaches for life-threatening conditions, highlighting its significance in the biotechnology sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
0
CEO
Country
Israel
IPO Year
N/A
Website
www.enlivex.comEnlivex Therapeutics Ltd. (ENLV) Latest News & Analysis
Latest News
Quick Summary
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) will present at the Israeli BioMed 2025 Conference on May 21-23, showcasing Allocetraâ„¢ and its potential in treating inflammatory diseases.
Why It Matters
The presentation at a major conference highlights Enlivex's innovative approach to inflammatory diseases, potentially boosting investor confidence and interest in its stock.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World Congress
1 month ago
Quick Summary
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) will present two poster abstracts on AllocetraTM's immune-targeting mechanism for joint disease at the OARSI World Congress from April 24-27, 2025.
Why It Matters
Enlivex's presentation at a major conference highlights its innovative approach to joint diseases, potentially attracting investor interest and impacting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Enlivex Therapeutics has completed patient enrollment for its Phase II trial of Allocetraâ„¢ for knee osteoarthritis, involving 133 patients. Topline data is expected by August 2025.
Why It Matters
Completion of patient enrollment in Enlivex's Phase II trial for Allocetraâ„¢ signals progress toward potential market approval. Positive topline data could boost stock value and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Enlivex Therapeutics has initiated a Phase I trial for Allocetraâ„¢ to treat TMJ osteoarthritis, a common condition with no effective long-term treatments. The first patient has been dosed.
Why It Matters
The trial of Allocetraâ„¢ could unlock a new treatment for TMJ osteoarthritis, potentially expanding Enlivex's market and impacting its share value positively if successful.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Enlivex Therapeutics (Nasdaq: ENLV) received a notice of allowance for its patent application from China's CNIPA, enhancing its intellectual property portfolio in macrophage reprogramming immunotherapy.
Why It Matters
Enlivex Therapeutics securing a patent in China enhances its competitive edge, potentially boosting its market value and attracting investment in its immunotherapy innovations.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Enlivex Therapeutics reported positive six-month interim efficacy data from its Phase I Allocetraâ„¢ trial for knee osteoarthritis, indicating progress in its clinical-stage immunotherapy.
Why It Matters
Positive interim results from Enlivex's Allocetraâ„¢ trial for knee osteoarthritis may enhance investor confidence, potentially boosting stock value and interest in the company's future developments.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ENLV Stock
What is Enlivex Therapeutics Ltd.'s (ENLV) stock forecast for 2025?
Based on our analysis of 3 Wall Street analysts, Enlivex Therapeutics Ltd. (ENLV) has a median price target of $10.00. The highest price target is $13.00 and the lowest is $7.00.
Is ENLV stock a good investment in 2025?
According to current analyst ratings, ENLV has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.98. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ENLV stock?
Wall Street analysts predict ENLV stock could reach $10.00 in the next 12 months. This represents a 925.6% increase from the current price of $0.98. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Enlivex Therapeutics Ltd.'s business model?
The company utilizes its proprietary Allocetra technology to create biopharmaceutical treatments that reprogram the immune system to address severe inflammatory conditions. It aims to generate revenue through the development and commercialization of these innovative therapies, targeting critical health issues like sepsis and other inflammatory diseases.
What is the highest forecasted price for ENLV Enlivex Therapeutics Ltd.?
The highest price target for ENLV is $13.00 from Jason Kolbert at D. Boral Capital, which represents a 1,233.3% increase from the current price of $0.98.
What is the lowest forecasted price for ENLV Enlivex Therapeutics Ltd.?
The lowest price target for ENLV is $7.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 617.9% increase from the current price of $0.98.
What is the overall ENLV consensus from analysts for Enlivex Therapeutics Ltd.?
The overall analyst consensus for ENLV is bullish. Out of 3 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $10.00.
How accurate are ENLV stock price projections?
Stock price projections, including those for Enlivex Therapeutics Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 24, 2025 5:55 AM UTC